Mechanisms of Damage to the Gastrointestinal Tract From Nonsteroidal Anti-Inflammatory Drugs

Nonsteroidal anti-inflammatory drugs (NSAIDs) can damage the gastrointestinal tract, causing widespread morbidity and mortality. Although mechanisms of damage involve the activities of prostaglandin-endoperoxide synthase 1 (PTGS1 or cyclooxygenase [COX] 1) and PTGS1 (COX2), other factors are involved. We review the mechanisms of gastrointestinal damage induction by NSAIDs via COX-mediated and COX-independent processes. NSAIDs interact with phospholipids and uncouple mitochondrial oxidative phosphorylation, which initiates biochemical changes that impair function of the gastrointestinal barrier. The resulting increase in intestinal permeability leads to low-grade inflammation. NSAID inhibition of COX enzymes, along with luminal aggressors, results in erosions and ulcers, with potential complications of bleeding, protein loss, stricture formation, and perforation. We propose a model for NSAID-induced damage to the gastrointestinal tract that includes these complex, interacting, and inter-dependent factors. This model highlights the obstacles for the development of safer NSAIDs. Nonsteroidal anti-inflammatory drugs (NSAIDs) can damage the gastrointestinal tract, causing widespread morbidity and mortality. Although mechanisms of damage involve the activities of prostaglandin-endoperoxide synthase 1 (PTGS1 or cyclooxygenase [COX] 1) and PTGS1 (COX2), other factors are involved. We review the mechanisms of gastrointestinal damage induction by NSAIDs via COX-mediated and COX-independent processes. NSAIDs interact with phospholipids and uncouple mitochondrial oxidative phosphorylation, which initiates biochemical changes that impair function of the gastrointestinal barrier. The resulting increase in intestinal permeability leads to low-grade inflammation. NSAID inhibition of COX enzymes, along with luminal aggressors, results in erosions and ulcers, with potential complications of bleeding, protein loss, stricture formation, and perforation. We propose a model for NSAID-induced damage to the gastrointestinal tract that includes these complex, interacting, and inter-dependent factors. This model highlights the obstacles for the development of safer NSAIDs. More than 30 million people take nonsteroidal anti-inflammatory drugs (NSAIDs) each day.1Singh G. Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications.J Rheumatol. 1999; 56: 18-24Google Scholar This number has grown significantly with increasing use of over-the-counter and prescription NSAIDs, low-dose aspirin, and after reports of their potential antineoplastic effects. The efficacy of NSAIDs as anti-inflammatory analgesics is not in doubt, but their adverse events are problematic. These relate mainly to cardiovascular, renal, hepatic, and gastrointestinal tissues. The cardiovascular adverse events have recently received much attention,2Bhala N. Emberson J. Merhi A. et al.Coxib and Traditional NSAID Trialists' (CNT) CollaborationVascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.Lancet. 2013; 382: 769-779Abstract Full Text Full Text PDF PubMed Scopus (1107) Google Scholar, 3Nissen S.E. Yeomans N.D. Solomon D.H. et al.Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis.N Engl J Med. 2016; 375: 2519-2529Crossref PubMed Scopus (424) Google Scholar but the frequency and severity of the gastrointestinal damage continues to cause concern. Accordingly, gastroduodenal ulcer rates range from 5% to 80% in short-term endoscopy studies4Bjarnason I. Scarpignato C. Takeuchi K. et al.Determinants of the short-term gastric damage caused by NSAIDs in man.Aliment Pharmacol Ther. 2007; 26: 95-106Crossref PubMed Scopus (0) Google Scholar and from 15% to 40% in long-term users.5Geis G.S. Stead H. Wallemark C.B. et al.Prevalence of mucosal lesions in the stomach and duodenum due to chronic use of NSAID in patients with rheumatoid arthritis or osteoarthritis, and interim report on prevention by misoprostol of diclofenac associated lesions.J Rheumatol Suppl. 1999; 28: 11-14Google Scholar NSAIDs also damage the small intestine6Bjarnason I. Hayllar J. Macpherson A.J. et al.Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine.Gastroenterology. 1993; 104: 1832-1847Abstract Full Text PDF PubMed Scopus (0) Google Scholar—as many as 70% of long-term users of NSAIDs have small intestinal inflammation, and 30% have erosions or ulcers.7Maiden L. Thjodleifsson B. Theodors A. et al.A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy.Gastroenterology. 2005; 128 (1172−118)Abstract Full Text Full Text PDF PubMed Scopus (330) Google Scholar The gastric and small bowel damage is associated with various management problems and, at times, life-threatening complications, such as bleeding, strictures, and perforations. There have been many studies of the pathogenesis of NSAID-induced gastrointestinal damage. NSAIDs inhibit prostaglandin-endoperoxide synthase 1 (PTGS1 or cyclooxygenase [COX] 1) and COX2, which were believed to mediate the gastrointestinal damage.8Vane J.R. Inhibition of prostaglandin synthesis as a mechanism of action of aspirin-like drugs.Nature. 1971; 231: 232-235Crossref Google Scholar, 9Whittle B.J. Arachidonic acid metabolites and the gastro-intestinal toxicity of anti-inflammatory agents.Prostaglandins. 1981; 21: 113-118Crossref PubMed Google Scholar, 10Vane J.R. Towards a better aspirin.Nature. 1994; 367: 215-216Crossref PubMed Scopus (693) Google Scholar NSAID-induced decreases in mucosal levels of prostaglandins (driven by inhibition of COX1) correlate with gastric and small bowel damage,11Whittle B.J.R. Temporal relationship between cyclooxygenase inhibition, as measured by prostacyclin biosynthesis, and gastrointestinal damage induced by indomethacin in the rat.Gastroenterology. 1981; 80: 94-98Abstract Full Text PDF PubMed Google Scholar, 12Peskar B.M. On the synthesis of prostaglandins by human gastric mucosa and its modification by drugs.Biochem Biophys Acta. 1977; 487: 307-314Crossref PubMed Scopus (0) Google Scholar, 13Strub K.M. Muller R.K. Relation between ulcerogenic activity of various NSAID and their potency as inhibitors of prostaglandin synthesis in vivo.Agents Actions. 1979; 4: 245-254Google Scholar which can be attenuated by administration of exogenous prostaglandins.14Graham D.Y. Agrawal N.M. Roth S.H. Prevention of NSAID-induced gastric ulcer with misoprostol: multicenter double blind, placebo-controlled trial.Lancet. 1988; (ii:1277−1280)Abstract Scopus (510) Google Scholar, 15Silverstein F.E. Graham G.Y. Senior J.R. et al.Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatoy drugs.Ann Int Med. 1995; 123: 241-249Crossref PubMed Google Scholar, 16Roberts A. Cytoprotection by prostaglandins.Gastroenterology. 1975; 77: 761-767Abstract Full Text PDF Google Scholar, 17Jiranek G.C. Kimmey M.B. Saunders D.R. et al.Misoprostol reduces gastroduodenal injury from one week of aspirin: an endoscopic study.Gastroenterology. 1989; 96: 656-661Abstract Full Text PDF PubMed Google Scholar, 18Bardhan K.D. Bjarnason I. Scott D.L. et al.The prevention and healing of acute NSAID-associated gastroduodenal mucosal damage by misoprostol.Br J Rheumatol. 1993; 32: 990-995Crossref PubMed Google Scholar Because COX2 is not constitutively expressed in the gastrointestinal tract, COX2 selective inhibitors are perceived as safer than conventional NSAIDs.14Graham D.Y. Agrawal N.M. Roth S.H. Prevention of NSAID-induced gastric ulcer with misoprostol: multicenter double blind, placebo-controlled trial.Lancet. 1988; (ii:1277−1280)Abstract Scopus (510) Google Scholar, 15Silverstein F.E. Graham G.Y. Senior J.R. et al.Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatoy drugs.Ann Int Med. 1995; 123: 241-249Crossref PubMed Google Scholar, 19Laine L. Takeuchi K. Tarnawski A. Gastric mucosal defense and cytoprotection: bench to bedside.Gastroenterology. 2008; 165: 41-60Abstract Full Text Full Text PDF Scopus (369) Google Scholar, 20Rostom A. Muir K. Dubé C.J. et al.Gastrointestinal safety of cyclooxygenase-2 inhibitors: a Cochrane Collaboration systematic review.Clin Gastroenterol Hepatol. 2007; 5: 818-828Abstract Full Text Full Text PDF PubMed Scopus (0) Google Scholar Proposed mechanisms of damage to the stomach involve prostaglandin-mediated increased gastric acid secretion, decreased mucus and bicarbonate secretion, decreased cell proliferation, and decreased mucosal blood flow.21Wallace J.L. Prostaglandins, NSAIDs, and gastric mucosal protection: why doesn't the stomach digest itself?.Physiol Rev. 2008; 88: 1547-1565Crossref PubMed Scopus (466) Google Scholar, 22Whittle B.J.R. Unwanted effects of aspirin and related agents on the gastrointestinal tract.in: Vane J.R. Botting R.M. Aspirin and other Salicylates. Chapman & Hall Medical, London1992: 465-509Google Scholar, 23Whittle B.J.R. Mechanism underlying gastric mucosal damage induced by indomethacin and bile salt, and the actions of prostaglandins.Br J Pharmacol. 1977; 60: 455-460Crossref PubMed Google Scholar, 24Whittle B.J.R. Protective mechanisms of the gastric mucosa.in: Gustsavsson S. Kumar D. Graham D.Y. The Stomach. Churchill Livingstone, Edinburgh1992: 81-101Google Scholar These are all actions that are detrimental to mucosal defense and healing, but the observed changes were only modest,21Wallace J.L. Prostaglandins, NSAIDs, and gastric mucosal protection: why doesn't the stomach digest itself?.Physiol Rev. 2008; 88: 1547-1565Crossref PubMed Scopus (466) Google Scholar, 23Whittle B.J.R. Mechanism underlying gastric mucosal damage induced by indomethacin and bile salt, and the actions of prostaglandins.Br J Pharmacol. 1977; 60: 455-460Crossref PubMed Google Scholar, 25Wallace J.L. Nonsteroidal anti-inflammatory drugs and gastroenteropathy: the second hundred years.Gastroenterology. 1997; 112: 1000-1016Abstract Full Text Full Text PDF PubMed Scopus (571) Google Scholar, 26Wallace J.L. McKnight G.W. The mucoid cap over superficial gastric damage in the rat. A high-pH microenvironment dissipated by nonsteroidal anti-inflammatory drugs and endothelin.Gastroenterology. 1990; 99: 295-304Abstract Full Text PDF PubMed Google Scholar, 27Wallace J.L. Caliendo G. Santagada V. et al.Gastrointestinal safety and anti-inflammatory effects of a hydrogen sulfide-releasing diclofenac derivative in the rat.Gastroenterology. 2007; 132: 261-271Abstract Full Text Full Text PDF PubMed Scopus (225) Google Scholar, 28Asako H. Kubes P. Wallace J. et al.Modulation of leukocyte adhesion in rat mesenteric venules by aspirin and salicylate.Gastroenterology. 1992; 103: 146-152Abstract Full Text PDF PubMed Google Scholar, 29McCafferty D.M. Granger D.N. Wallace J.L. Indomethacin-induced gastric injury and leukocyte adherence in arthritic versus healthy rat.Gastroenterology. 1995; 109: 1173-1180Abstract Full Text PDF PubMed Scopus (0) Google Scholar, 30Whittle B.J.R. Kaufman G.L. Moncada S. Vasoconstriction with thromboxane A2 induces ulceration of gastric mucosa.Nature. 1981; 292: 472-474Crossref PubMed Google Scholar and the damage seemed to lack an initiative action. Furthermore, decreased mucosal prostaglandins have been found to be less important in the pathogenesis of small bowel damage.11Whittle B.J.R. Temporal relationship between cyclooxygenase inhibition, as measured by prostacyclin biosynthesis, and gastrointestinal damage induced by indomethacin in the rat.Gastroenterology. 1981; 80: 94-98Abstract Full Text PDF PubMed Google Scholar, 31Wallace J.L. The 1994 Merk Frosst Award. Mechanism of nonsteroidal anti-inflammatory drug (NSAID) induced gastrointestinal damage-potential for development of gastrointestinal tract safe NSAIDs.Can J Physiol Pharmacol. 1994; 72: 1493-1498Crossref PubMed Google Scholar, 32Syer S.D. Blackler R.W. Martin R. et al.NSAID enteropathy and bacteria: a complicated relationship.J Gastroenterol. 2015; 50: 387-393Crossref PubMed Scopus (10) Google Scholar Further studies found that gastric and small bowel mucosal prostaglandins could be decreased by 95%−98% without mucosal damage,33Ligumski M. Golanska E.M. Hansen D.G. et al.Aspirin can inhibit gastric mucosal cyclo-oxigenase without causing lesions in the rat.Gastroenterology. 1983; 84: 756-761Abstract Full Text PDF PubMed Scopus (181) Google Scholar, 34Ligumski M. Sestieri M. Karmeli F. et al.Rectal administration of nonsteroidal antiinflammatory drugs.Gastroenterology. 1990; 98: 1245-1249Abstract Full Text PDF PubMed Scopus (59) Google Scholar, 35Langenbach R. Morham S.G. Tiano H.F. et al.Prostaglandin synthase 1 gene disruption in mice reduced arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration.Cell. 1995; 83: 483-492Abstract Full Text PDF PubMed Google Scholar and confirmed in COX1-knockout mice.35Langenbach R. Morham S.G. Tiano H.F. et al.Prostaglandin synthase 1 gene disruption in mice reduced arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration.Cell. 1995; 83: 483-492Abstract Full Text PDF PubMed Google Scholar, 36Sigthorsson G. Simpson R.J. Walley M. et al.COX-1 and 2, intestinal integrity, and pathogenesis of nonsteroidal anti-inflammatory drug enteropathy in mice.Gastroenterology. 2002; 122: 1913-1923Abstract Full Text Full Text PDF PubMed Google Scholar, 37Wallace J.L. McKnight W. Reuter B.K. et al.NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2.Gastroenterology. 2000; 119: 706-714Abstract Full Text Full Text PDF PubMed Google Scholar Short-term loss or inhibition of COX2 does not cause damage, but small bowel damage is evident in mice and humans exposed to NSAIDs for long periods of time.38Takeuchi K. Smale S. Premchand P. et al.Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease.Clin Gastroenterol Hepatol. 2006; 4: 196-202Abstract Full Text Full Text PDF PubMed Scopus (0) Google Scholar, 39Morham S.G. Langenbach R. Loftin C.D. et al.Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse.Cell. 1995; 83: 473-482Abstract Full Text PDF PubMed Scopus (1008) Google Scholar, 40Sigthorsson G. Crane R. Simon T. et al.COX-2 specific inhibition with rofecoxib 25 or 50 mg OD does not increase intestinal permeability: a controlled study with placebo and indomethacin 50 mg TID.Gut. 2000; 47: 527-532Crossref PubMed Scopus (0) Google Scholar, 41Maiden L. Thjodleifsson B. Seigal A. et al.Long-term effects of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective agents on the small bowel: a cross-sectional capsule enteroscopy study.Clin Gastroenterol Hepatol. 2007; 5: 1040-1045Abstract Full Text Full Text PDF PubMed Scopus (213) Google Scholar Dual inhibition of COX1 and COX2 causes gastric and small bowel lesions, albeit somewhat less severe than the lesions caused by conventional acidic NSAIDs.36Sigthorsson G. Simpson R.J. Walley M. et al.COX-1 and 2, intestinal integrity, and pathogenesis of nonsteroidal anti-inflammatory drug enteropathy in mice.Gastroenterology. 2002; 122: 1913-1923Abstract Full Text Full Text PDF PubMed Google Scholar So, inhibition of COX does not seem to be the only mechanism of NSAID-induced gastrointestinal damage. We review the prostaglandin-independent mechanisms of NSAIDs and how these interact with the consequence of alterations in prostaglandin due to COX inhibition. We provide a model in which COX inhibition is one of several important factors in the pathogenesis of gastrointestinal damage (see Figure 1). Our model considers the effects of the specific biochemical “topical” actions of NSAIDs (ie, the effects that occur by direct contact between the NSAIDs in the lumen and mucosal epithelium after oral ingestion or biliary excretion of the drugs, as opposed to topical skin application) and the consequential increase in intestinal permeability and intestinal inflammation. These initiate damage and inhibition of COX1 and COX2 aggravate it, along with luminal aggressors, leading to development of erosions and ulcers.42Somasundaram S. Hayllar J. Rafi S. et al.The biochemical basis of NSAID-induced damage to the gastrointestinal tract: a review and a hypothesis.Scand J Gastroenterol. 1995; 30: 289-299Crossref PubMed Scopus (0) Google Scholar, 43Bjarnason I. Takeuchi K. Bjarnason A. et al.The G.U.T. of gut.Scand J Gastroenterol. 2004; 39: 807-815Crossref PubMed Scopus (28) Google Scholar The biochemical actions common to all conventional NSAIDs are their topical effects, and inhibition of COX1 and COX2. These biochemical actions are brought about by the physicochemical properties that NSAIDs share,44Brune K. Glatt M. Graf P. Mechanisms of action of anti-inflammatory drugs.Gen Pharmacol. 1976; 7: 27-33Crossref PubMed Google Scholar, 45Brune K. Graf P. Rainsford K.D. Biodistribution of acidic anti-inflammatory drugs: a clue to the understanding of their effects and side-effects.Drug Exp Clin Res. 1977; 2: 155-168Google Scholar, 46Rainsford K.D. Structure-activity relationships of non-steroidal anti-inflammatory drugs. I. Gastric ulcerogenic activity.Agents Actions. 1978; 8: 587-605Crossref PubMed Google Scholar namely being lipid-soluble weak acids (see Figure 2). This combination provides them with detergent action (interaction with phospholipids), uncoupling of oxidative phosphorylation, and noncovalent inhibition of COX1 and COX2. These biochemical activities depend on the same physical and chemical characteristics, so changing these will change all of the pharmacologic actions. For example, esterification of NSAIDs47Rainsford K.D. Whitehouse M.W. Anti-inflammatory antipyretic salicylic acid esters, with low gastric ulcerogenic activity.Agents Actions. 1980; 10: 451-456Crossref PubMed Google Scholar causes loss of their topical effects and, at the same time, their ability to inhibit the COX enzymes. NSAIDs interact with the intestinal mucus layer and the cell surface phospholipid bilayer. There are subtle differences in mucus thickness and composition in different regions of the gastrointestinal tract.19Laine L. Takeuchi K. Tarnawski A. Gastric mucosal defense and cytoprotection: bench to bedside.Gastroenterology. 2008; 165: 41-60Abstract Full Text Full Text PDF Scopus (369) Google Scholar, 48Varum F.J. Veiga F. Sousa J.S. et al.An investigation into the role of mucus thickness on mucoadhesion in the gastrointestinal tract of pig.Eur J Pharm Sci. 2010; 40: 335-341Crossref PubMed Scopus (25) Google Scholar The role of mucus is to act as a lubricant between the surface epithelium and the luminal contents, restricting access of large hydrophilic molecules, digestive enzymes, and bacteria to the surface epithelium. In the stomach, mucus also buffers luminal acids. The production and secretion of mucus is determined by interactions between luminal aggressors (acid, pepsin, and Helicobacter pylori in the stomach and bile and bacteria in the small bowel) and the surface epithelium mediated by numerous factors, such as inflammatory cytokines and prostaglandins. Mucus serves as a matrix for phospholipids that maintain gastrointestinal integrity.49Lichtenberger L.M. Wang Z.-M. Romero J.J. et al.Non-steroidal anti-inflammatory drugs (NSAIDs) associate with zwitterionic phospholipids: insight into the mechanism and reversal of NSAID-induced gastrointestinal injury.Nat Med. 1995; 1: 154-158Crossref PubMed Google Scholar Like NSAIDs, phospholipids are amphiphilic molecules, with a hydrophilic polar head group and a hydrophobic tail region. The integrity of the mucus layer can be assessed by various methods.50Lichtenberger L.M. The hydrophobic barrier properties of gastrointestinal mucus.Annu Rev Physiol. 1995; 57: 565-583Crossref PubMed Google Scholar NSAIDs decreased the hydrophobicity in the gastroduodenal mucosa,51Goddard P.J. Hills B.A. Lichtenberger L.M. Does aspirin damage canine gastric mucosa by reducing its surface hydrophobicity?.Am J Physiol. 1987; 252: G421-G430PubMed Google Scholar an effect seen also after parenteral administration via the biliary excretion of the drug.52Lugea A. Antolin M. Mourelle M. et al.Deranged hydrophobic barrier of the rat gastroduodenal mucosa after parenteral nonsteroidal anti-inflammatory drugs.Gastroenterology. 1997; 112: 1931-1939Abstract Full Text Full Text PDF PubMed Scopus (0) Google Scholar The interaction between NSAIDs and phospholipids compromises the hydrophobic lining, which leads to mucosal exposure to luminal aggressors (acid and pepsin in the stomach and bacteria and bile in the small intestine). The concept of a hydrophobic barrier attributed to phospholipids and the binding of NSAIDs to dipalmitoylphosphatidylcholine (the dominant phospholipid in the gastrointestinal tract), in vitro and in vivo,49Lichtenberger L.M. Wang Z.-M. Romero J.J. et al.Non-steroidal anti-inflammatory drugs (NSAIDs) associate with zwitterionic phospholipids: insight into the mechanism and reversal of NSAID-induced gastrointestinal injury.Nat Med. 1995; 1: 154-158Crossref PubMed Google Scholar, 53Lichtenberger L.M. Zhou Y. Jayaraman V. et al.Insight into NSAID-induced membrane alterations, pathogenesis and therapeutics: characterization of interaction of NSAIDs with phosphatidylcholine.Biochem Biophys acta. 2012; 182: 994-1002Google Scholar led to a series of studies investigating the effect of orally coadministrated phospholipids with NSAIDs, and other toxic compounds, with a view to diminishing their toxicity. Combining NSAIDs with the phospholipid phosphatidylcholine protects against NSAID-induced gastric49Lichtenberger L.M. Wang Z.-M. Romero J.J. et al.Non-steroidal anti-inflammatory drugs (NSAIDs) associate with zwitterionic phospholipids: insight into the mechanism and reversal of NSAID-induced gastrointestinal injury.Nat Med. 1995; 1: 154-158Crossref PubMed Google Scholar, 54Lichtenberger L.M. Ulloa C. Romero J.J. et al.Nonsteroidal anti-inflammatory drug and phospholipid prodrugs: combination therapy with antisecretory agents in rats.Gastroenterology. 1996; 111: 990-995Abstract Full Text PDF PubMed Google Scholar and small bowel55Lim Y.J. Phan T.M. Dial E.J. et al.In vitro and in vivo protection against indomethacin-induced small intestinal injury by proton pump inhibitors, acid pump antagonists, or indomethacin-phosphatidylcholine.Digestion. 2012; 86: 171-177Crossref PubMed Scopus (22) Google Scholar damage in short-term rodent studies. Lichtenberger et al56Lichtenberger L.M. Romero J.J. Dial E.J. Surface phospholipids in gastric injury and protection when a selective cyclooxygenase-2 inhibitor (Coxib) is used in combination with aspirin.Br J Pharmacol. 2007; 150: 913-919Crossref PubMed Scopus (33) Google Scholar demonstrated decreased gastric toxicity of the otherwise damaging combination of aspirin and a COX2-selective agent, if the aspirin was coadministered with a phospholipid. These and other animal studies provided the platform for testing the safety of NSAIDs combined with phospholipids in humans. Volunteers were given aspirin or a combination of aspirin and phospholipid (650 mg aspirin/d for 3 days). The number of gastric erosions (assessed during endoscopy) was significantly lower in volunteers given aspirin and phospholipid (mean 2.8 ± 4.3) than aspirin alone (mean 8.8 ± 10.8); both drugs reduced mucosal prostaglandin content to the same extent.57Anand B.S. Romero J.J. Sanduja S.K. et al.Phospholipid association reduces the gastric mucosal toxicity of aspirin in human subjects.Am J Gastroenterol. 1999; 94: 1818-1822Crossref PubMed Scopus (99) Google Scholar In a separate study, healthy volunteers given aspirin (325 mg/d for 7 days) or the same amount of aspirin combined with phosphatidylcholine had a significant decrease in gastric ulcers, from 17.6% in volunteers given aspirin to 5.1% in volunteers given aspirin with phosphatidylcholine.58Cryer B. Bhatt D.L. Lanza F.L. et al.Low-dose aspirin-induced ulceration is attenuated by aspirin-phosphatidylcholine: a randomized clinical trial.Am J Gastroenterol. 2011; 106: 272-277Crossref PubMed Scopus (75) Google Scholar In a 6-week study of patients with osteoarthritis, the combination of ibuprofen and phosphatidylcholine was associated with significant improvements in Lanza gastroscopy scores compared to patients given ibuprofen (2400 mg) alone, but only in patients older than 55 years.59Lanza F.L. Marathi U.K. Anand B.S. et al.Clinical trial: comparison of ibuprofen-phosphatidylcholine and ibuprofen on the gastrointestinal safety and analgesic efficacy in osteoarthritic patients.Aliment Pharmacol Ther. 2008; 28: 431-442Crossref PubMed Scopus (0) Google Scholar These studies demonstrated greater gastric tolerability of combinations of aspirin and phospholipid, in the short-term, in humans, in which damage is more likely to be caused by the physicochemical properties of NSAIDs than their effect on COX1 or COX2.4Bjarnason I. Scarpignato C. Takeuchi K. et al.Determinants of the short-term gastric damage caused by NSAIDs in man.Aliment Pharmacol Ther. 2007; 26: 95-106Crossref PubMed Scopus (0) Google Scholar Mitochondria are the main source of adenosine triphosphate (ATP) in cells. Mitochondrial ATP synthesis takes place by integrated biochemical-physiological-physical processes60Tyler D.D. Respiratory enzyme systems of mitochondria.in: Tyler D.D. The Mitochondrian in Health and Disease. VCH Publishers, New York1992: 270-351Google Scholar (see Figure 3). Whatever the cause of uncoupling, there is a cascade of detrimental downstream effects: water flows into the matrix causing characteristic and pathognomonic swelling of mitochondria. There is release of intra-mitochondrial Ca2+ into cytoplasm with depletion of reduced glutathione, depletion of NAD(P)H2, generation of superoxide anion (O2−), and release of pro-apoptogenic proteins.61Zamzami N. Susin S.A. Marchetti P. et al.Mitochondrial control of nuclear apoptosis.J Exp Med. 1996; 183: 1533-1544Crossref PubMed Scopus (1251) Google Scholar Free radicals accumulate within the mitochondria, setting up a vicious cycle, as this activates uncoupling proteins in the inner mitochondrial membrane.62Sivalingam N. Basivireddy J. Balasubramanian K.A. et al.Curcumin attenuates indomethacin-induced oxidative stress and mitochondrial dysfunction.Arch Toxicol. 2008; 82: 471-481Crossref PubMed Scopus (0) Google Scholar The uncoupling ultimately leads to depletion of cellular ATP levels, with loss of integrity of the intercellular junctions in the gastrointestinal tract (leading to increased mucosal permeability)63Madara J.L. Tight junction dynamics: is paracellular transport regulated?.Cell. 1988; 53: 497-498Abstract Full Text PDF PubMed Google Scholar and, ultimately, apoptosis and cell death.64Masubuchi Y. Saito H. Horie T. Structural requirements for the hepatotoxicity of nonsteroidal anti-inflammatory drugs in isolated rat hepatocytes.J Pharmacol Exp Ther. 1998; 287: 208-213PubMed Google Scholar Well before the understanding that NSAIDs inhibited the COX enzyme(s), it was evident that NSAIDs were uncouplers of mitochondrial oxidative phosphorylation.65Adams S.S. Cobb R. A possible basis for the anti-inflammatory activity of salicylates and other non-hormonal anti-rheumatic drugs.Nature. 1958; 181: 773-774Crossref PubMed Scopus (0) Google Scholar, 66Adams S.S. Cliffe E.E. Lessel B. et al.Some biological properties of ‘ibufenac', a new anti-rheumatic drug.Nature. 1963; 200: 271-272Crossref PubMed Scopus (0) Google Scholar Adams et al65Adams S.S. Cobb R. A possible basis for the anti-inflammatory activity of salicylates and other non-hormonal anti-rheumatic drugs.Nature. 1958; 181: 773-774Crossref PubMed Scopus (0) Google Scholar screened possible anti-inflammatory agents based on their uncoupling properties and several (such as ibuprofen, naproxen, and indomethacin) have been marketed on that basis. However, the idea of the uncoupling action of NSAIDs as a mechanism for their therapeutic actions became obsolete when the prostaglandin hypothesis gained momentum. A few reports describe uncoupling of mitochondrial oxidative phosphorylation in the gastric mucosa after aspirin.67Glarborg-Jorgensen T. Weis-Fogh U.S. Neilsen H.H. et al.Salicylate- and aspirin-induced uncoupling of oxidative phosphorylation in mitochondria isolated from the mucosal membrane of the stomach.Scand J Lab Invest. 1976; 36: 649-653Crossref PubMed Google Scholar, 68Spenny J.G. Bhown M. Effect of prostaglandin acid on gastric mucosa II. Mucosal ATP and phosphocreatinine content and salicylic effects on mitochondrial metabolism.Gastroenterology. 1977; 73: 995-999PubMed Google Scholar The technique of selective sub-cellular marker enzyme analyses of small bowel mucosa after administration of NSAIDs in animals69Somasundaram S. Rafi S. Hayllar J. et al.Mitochondrial damage: a possible mechanism of the “topical” phase of NSAID-induced injury to the rat intestine.Gut. 1997; 41: 344-353Crossref PubMed Google Scholar showed a significant change in the brush border marker enzymes, compatible with the interaction of NSAIDs with phospholipids and the mitochondrial marker enzymes. Electron microscopic changes of uncoupling were demonstrated in vivo after administration of NSAIDs to rats.69Somasundaram S. Rafi S. Hayllar J. et al.Mitochondrial damage: a possible mechanism of the “topical” phase of NSAID-induced injury to the rat intestine.Gut. 1997; 41: 344-353Crossref PubMed Google Scholar The in vitro uncoupling of conventional acidic (carboxylic or enolic acids) NSAIDs relates to their logarithmic transformed acid dissociation constant (pKa)